Theravance Biopharma Inc (TBPH) — Financial statements
Income statement, balance sheet, and cash flow for Theravance Biopharma Inc — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 107↑66.9% | 64↑12.1% | 57↑11.8% | 51↓7.2% | 55 | |
| Cost of Revenue | 6 | 0.00↓100.0% | 41↓35.9% | 63↓67.3% | 194 | |
| Gross Profit | 102↑58.4% | 64↑283.2% | 17↑239.5% | -12↑91.3% | -138 | |
| Operating Expenses | ||||||
| R&D Expenses | 37↓0.6% | 38↓18.8% | 46↓33.9% | 70↓65.2% | 202 | |
| General & Administrative Expenses | 0.00↓100.0% | 65↓0.7% | 65↑10.6% | 59 | 0.00 | |
| Selling & Marketing Expenses | 0.00↓100.0% | 4↓15.7% | 5↓36.3% | 8 | 0.00 | |
| SG&A Expenses | 74↑6.5% | 69↓1.8% | 70↑5.0% | 67↓32.5% | 99 | |
| Other Expenses | 4↓8.5% | 5↑110.3% | -44↑23.2% | -57↑68.4% | -181 | |
| Operating Expenses | 115↑3.5% | 111↑52.8% | 73↓8.9% | 80↓33.1% | 119 | |
| Total Costs & Expenses | 121↑8.4% | 111↓1.9% | 113↓20.8% | 143↓54.2% | 313 | |
| Operating Results | ||||||
| Operating Income | -13↑71.8% | -47↑16.2% | -56↑39.1% | -92↑64.3% | -258 | |
| Depreciation & Amortization | 6↑52.6% | 4↑80.7% | 2↓34.1% | 3↓36.9% | 5 | |
| EBITDA | -8↑79.9% | -38↑25.5% | -52↑32.1% | -76↑67.3% | -233 | |
| EBIT | -13↑68.5% | -42↑21.6% | -54↑32.2% | -79↑66.7% | -238 | |
| Interest & Other Income | ||||||
| Net Interest Income | -2↓205.4% | 2↓65.5% | 7↑210.9% | 2↑129.3% | -7 | |
| Interest Income | 0.00↓100.0% | 5↓46.5% | 9↑6.7% | 9↑670.5% | 1 | |
| Interest Expense | 2↓3.3% | 3↑8.3% | 2↓63.1% | 6↓25.5% | 9 | |
| Non-Operating Income | 0.00↑100.0% | -5↓104.6% | -2↑81.4% | -13↑36.3% | -20 | |
| Other Income / Expenses | 142↑6002.5% | 2↓65.5% | 7↑888.6% | -0.86↑88.5% | -7 | |
| Income Before Tax | 129↑389.7% | -45↑9.4% | -49↑46.9% | -93↑65.0% | -265 | |
| Income Tax Expense | 23↑97.8% | 12↑99.3% | 6↑65722.2% | 0.01↑106.0% | -0.15 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 106↑287.7% | -56↓2.2% | -55↑40.5% | -93↑65.0% | -265 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00↓100.0% | 965↑1370.0% | 66 | |
| Net Income | 106↑287.7% | -56↓2.2% | -55↓106.3% | 872↑537.3% | -199 | |
| Bottom-Line Net Income | 106↑287.7% | -56↓2.2% | -55↑40.5% | -93↑65.0% | -265 | |
| EPS (Basic) | 2.10↑282.6% | -1.15↓15.0% | -1.00↑20.6% | -1.26↑56.1% | -2.87 | |
| EPS (Diluted) | 2.06↑279.1% | -1.15↓15.0% | -1.00↑20.6% | -1.26↑56.1% | -2.87 | |
| Weighted Average Shares | 50↑3.0% | 49↓11.7% | 55↓24.9% | 74↑5.9% | 69 | |
| Weighted Average Diluted Shares | 52↑5.4% | 49↓11.7% | 55↓24.9% | 74↑5.9% | 69 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.